Evidence map›Paper›PMID 40913132›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Quantification of monoamine oxidase B expression with

Kiwamu Matsuoka, Yuhei Takado, Yasuyuki Kimura, Akihiko Kitamura, Hitomi Kitamura, Mayuka Kanda, Michihiro Takada, Maiko Ono, Harutsugu Tatebe, Hironobu Endo and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Reliable One-Pot Automated Preparation of [Journal of labelled compounds & radiopharmaceuticals · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Kiwamu MatsuokaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan. matsuoka.kiwamu@qst.go.jp.ORCID 0000-0003-3263-0958
Yuhei TakadoInstitute for Quantum Life Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan. takado.yuhei@qst.go.jp.ORCID 0000-0001-7484-8424
Yasuyuki KimuraAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan. yazkim@ncgg.go.jp.ORCID 0000-0002-7927-9483
Akihiko KitamuraAjinomoto Co., Inc, Kawasaki, Japan.
Hitomi KitamuraAjinomoto Co., Inc, Kawasaki, Japan.
Mayuka KandaAjinomoto Co., Inc, Kawasaki, Japan.
Michihiro TakadaAjinomoto Co., Inc, Kawasaki, Japan.
Maiko OnoInstitute for Quantum Life Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.ORCID 0000-0003-2239-1754
Harutsugu TatebeAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Hironobu EndoAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Shin KuroseAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Keisuke TakahataAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Yoko IkomaDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Masanori IchihashiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Masaki OyaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Kosei HirataAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Hideki MatsumotoAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Asumi OriharaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Naomi KokuboAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Yuko KataokaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Hong ZhangAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Kenji TagaiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Chie SekiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Hitoshi ShinotohAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Tatsuya KikuchiDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Masanori IchiseAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Hiroshi ShimizuDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Kazunori KawamuraDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Hitoshi ShimadaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Kenji NagaoAjinomoto Co., Inc, Kawasaki, Japan.
Takahiko TokudaAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.
Makoto HiguchiAdvanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Chiba-shi, Chiba, 263-8555, Japan.

Funding

Ajinomoto Co., Inc. Ajinomoto Co., Inc.Japan Science and Technology Agency JP19dm0207072Japan Science and Technology Agency JP21zf0127004Japan Science and Technology Agency JP22dk0207055Japan Science and Technology Agency JP22dk0207063Japan Science and Technology Agency JP24zf0127012
6 · The paper itself

Abstract

purposeAstrocyte reactivation can be assessed using positron emission tomography (PET) ligands targeting monoamine oxidase B (MAO-B).

methodsSix patients with mild cognitive impairment (MCI), five patients with AD, and six healthy controls (HCs) underwent

resultsA strong agreement was observed between the DVRs estimated using MRTM

conclusionMAO-B density in patients with MCI/AD can be accurately estimated by calculating DVRs using a simplified quantification method that does not require arterial blood sampling. The estimated MAO-B density shows an increase that peaks at the MCI stage, suggesting early astrocyte reactivation in the progression of AD pathology.

Indexed as

Alzheimer DiseaseAstrocytesMonoamine OxidasePositron-Emission TomographyAgedCarbon RadioisotopesCognitive DysfunctionFemaleHumansMaleMiddle AgedCarbon-11Carbon RadioisotopesMonoamine OxidaseAlzheimer's diseaseDistribution volume ratiosMonoamine oxidase bPositron emission tomography

Identifiers

PMID40913132
PMCPMC12830491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.